• No results found

FORMULATION AND IN VITRO EVALUATION OF DAPAGLIFLOZIN AND SAXAGLIPTIN BILAYERED TABLETS

N/A
N/A
Protected

Academic year: 2020

Share "FORMULATION AND IN VITRO EVALUATION OF DAPAGLIFLOZIN AND SAXAGLIPTIN BILAYERED TABLETS"

Copied!
10
0
0

Loading.... (view fulltext now)

Full text

Figure

Table 1: Interpretation of Dapagliflozin and Saxagliptin (pure drugs) FT-IR spectra
Table 6: Diffusion exponent and drug release mechanisms for cylindrical shape (Korsemeyer-Peppas model)
Table 8: Results of post-compression parameters of accelerated stability samples of optimized
Fig. 3: Comparative in vitro dissolution profiles of Dapagliflozin immediate release tablets
+2

References

Related documents

The parametrization used here leads to a differential addition formula, a doubling formula and a tripling formula on elliptic curves in generalized Edwards form.. We also

We also compared the AUC of machine learning using the network topology to the logis- tic regression based on the standard financial measures (non-network information): firm

An English translation (accuracy confirmed by back translation) of the two ques- tionnaires on personal preference is shown in Table 1. Similar statements with appropriate

[19] using finite element analysis (FEA) concluded that the elastics have to be applied with a variable downward direction of about 30° to the occlusal plane in order to control

The successful development of Kuxun, from a train ticket search engine to a comprehensive brand of consumer information search in the domestic market, and eventually the leader

Mit dem Ziel eine effektive internationale Vergleichbarkeit der Ergebnisse zu erreichen, wurde 1987 in New York das International Knee Documentation Committee (IKDC)

It then discusses the impact of these reforms on the corporate sector under five main heads: corporate governance, risk management, capital structure, group structure and

Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Hayes